WHK-001
Advanced Solid Tumors (including Recurrent Glioblastoma and NSCLC)
Key Facts
Indication
Advanced Solid Tumors (including Recurrent Glioblastoma and NSCLC)
Phase
Phase 1/2
Status
Active, Recruiting
Company
About Whitehawk Therapeutics
Whitehawk Therapeutics is pioneering a new class of oral immunotherapies that target key metabolic enzymes in the tumor microenvironment to overcome immune resistance. The company's platform focuses on modulating the kynurenine pathway, specifically inhibiting TDO2 and IDO1, to restore effective anti-cancer immunity. With its lead candidate, WHK-001, advancing in clinical trials for solid tumors, Whitehawk aims to address significant unmet needs in oncology. The company leverages deep expertise in immuno-oncology and small molecule drug discovery to develop potentially transformative treatments.
View full company profile